EMEA's consideration on strategy and design of clinical trials for new antibacterial agent;

FDA's general considerations on the antibacterial dugs clinical trial protocol issues and its enlightenment;

FDA's considerations of non-inferiority design used in anti-bacterial drug clinical trials;

Objective index for evaluating cerebral atherosclerosis in clinical trails;

Issues of clinical trails on traditional Chinese new drugs for diabetic polyneuropathy;

Some problems on clinical trails evalution of herbs medicine for insomnia;

Several Points in Ethic Review in Drug Clinical Trials;

Simulations of urn model and RPW rule of adaptive design in clinical trials;

Main points of design about phase I tolerant clinical trials of injectable preparation;

Method The clinical test of multicentric random parallel control was used.

Methods:Through the relevant exprinents and analysis of documental materials, by summarizing the information about the source of ursolic acid and its feature of physics and chemistry, through identification and measure of its structure and content by analysis of its pharmacological functions and by clinical tests and studies on the productive technology.